SEC Form 4 · accession 0001209191-16-150862

Atara Biotherapeutics, Inc. · ATRA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief R & QA Officer

Period of report

Nov 15, 2016

Accepted (ET)

Nov 17, 2016 · 4:28 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001604464

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Nov 15, 2016	M	7,212	$0.00	A	98,182	D
Common Stock	Nov 16, 2016	S	2,995	$19.53	D	95,187	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Unites^F4,F5,F6	—	Nov 15, 2016	M	7,212	D	—	—	Common Stock	7,212	40,865	D

F1Shares issued upon settlement of vested restricted stock units ("RSUs").
F2Shares sold to cover tax obligation from settlement of vested restricted stock units.
F3Transaction pursuant to Rule 10b5-1 Plan adopted October 12, 2016.
F4Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement.
F5The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 17, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date.
F6The earlier of (i) March 27, 2021 or (ii) the recepient's termination date.